Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Inyta

- PMLiVE

Pfizer concludes NextWave acquisition

Sets company up to compete in the ADHD sector

- PMLiVE

NICE backs Servier’s heart failure drug Procoralan

But recommendation includes a number of restrictions that limit NHS use of the drug

Zogenix appoints Pfizer’s R Scott Shively as chief commercial officer

Was VP global commercial disease area lead for pain at Pfizer

- PMLiVE

Postcards from China, part 3

Improving market access through integrated solutions

Novartis building

Novartis to issue stark warning to UK at crisis meeting

Says UK needs to address decline in pharma R&D

Drug pricing in Ireland

Sustained pressure on healthcare spending, combined with the continued impact of patent expiries, could thwart the pharma industry in Ireland

- PMLiVE

Eliquis cleared in EU for stroke prevention in AF

Follows last year’s approval for the prevention of VTE after surgery for BMS and Pfizer's drug

- PMLiVE

Cystic fibrosis group pledges $58m to Pfizer discovery programme

Pharma company forms public-private partnership with Cystic Fibrosis Foundation

- PMLiVE

NICE rejects Pierre Fabre’s bladder cancer drug Javlor

Says drug received final draft 'no' because pharma company failed to prove efficacy

- PMLiVE

NICE to reverse approval for Novartis’ asthma drug Xolair

Draft guidance doesn't recommend omalizumab for severe asthma

- PMLiVE

Pfizer’s arthritis hope Xeljanz gets US approval

Could present a major challenge to existing biologic treatments like Humira and Orencia

- PMLiVE

Pfizer helps fund biotech venture from former researchers at closed Kent facility

Ziarco headed by former Pfizer chief scientific officer, allergy and respiratory research, Mike Yeadon

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links